Dimitrios Zardavas

Dimitrios Zardavas

Bristol-Myers Squibb Co. - New York / United States
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4394420
-
person_outline Dimitrios Zardavas's MOST POPULAR ARTICLES
1-) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancerG Von Minckwitz, M Procter, E de Azambuja, D Zardavas, M Benyunes, ...New England Journal of Medicine 377 (2), 122-131, 201711362017
2-) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinomaDF Bajorin, JA Witjes, JE Gschwend, M Schenker, BP Valderrama, ...New England Journal of Medicine 384 (22), 2102-2114, 20215922021
3-) Clinical management of breast cancer heterogeneityD Zardavas, A Irrthum, C Swanton, M PiccartNature reviews Clinical oncology 12 (7), 381-394, 20155722015
4-) Luminal B breast cancer: molecular characterization, clinical management, and future perspectivesF Ades, D Zardavas, I Bozovic-Spasojevic, L Pugliano, D Fumagalli, ...Journal of clinical oncology 32 (25), 2794-2803, 20145102014
5-) Progress in adjuvant systemic therapy for breast cancerNF Pondé, D Zardavas, M PiccartNature reviews Clinical oncology 16 (1), 27-44, 20192682019